• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

In order to ensure your "Under Consideration" USAN domain name is available, USAN applicants should consider purchasing the .com, .net, and .org domain names of your USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following list of names for the drugs described are "under consideration" by the USAN Council:

June 2015

metdioxymetamfetamine adjunct to psychotherapy in the treatment of PTSD
naquotinib treatment of lung cancer
tigralisib antineoplastic

May 2015

bunesumab treatment of X-linked hypophosphatemia
istriratumab treatment of advanced solid tumors
suptavumab prevention of respiratory disease due to RSV
vestaronidase enzyme replacement therapy
vestronidase enzyme replacement therapy
vonasonstat treatment of cystic fibrosis

April 2015

dexisometheptene treatment of episodic tension-type headache; migraine